Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02442011 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Hematology Biobank: In Vitro Study of Blood Disorders

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment target: 1000 to 2000v12 Show 4 more changesShow less
    • Eligibility criteria expanded, about 23 words
    • Study description expanded, about 101 words
    • Study title revised
    • Collaborators expanded, about 4 words
  2. Primary and study completion dates: Dec 2025 to Jan 2030v11
  3. 4 versions Re-verified since Nov 11, 2020, no change to tracked fieldsv7-v10
  4. Primary completion date: Dec 2019 to Dec 2025v6
  5. 4 versions Re-verified since Dec 28, 2015, no change to tracked fieldsv2-v5
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a biorepository of blood specimens from subjects with different Hematological disorders.
Trial Details
NCT Number NCT02442011
Lead Sponsor Albert Einstein College of Medicine
Collaborators: New York Blood Center
Conditions
(from sponsor)		 Hematological Disorders
Related terms Hematologic Diseases
Enrollment 2,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov